• There are no suggestions because the search field is empty.

The DocTalk series, where we discuss current events in the industry and what they might mean for you. From news articles, research studies, pop culture, and everything in between, we’re going to break it all down and sift through the noise with the help of our expert, Dr. Janet Choi, Progyny’s Chief Medical Officer.

Today we’re spotlighting a study that’s been turning heads. This pilot study investigates how repurposing low doses of rapamycin, a drug originally used for patients undergoing an organ transplant, could potentially delay ovarian aging in women. While this pilot study shows promise, it’s clear more research is needed. Listen to Dr. Choi unpack the science behind rapamycin and ovarian reserve, what this study found, and what this could mean for the future of fertility and women’s health.

Experts:
Dr. Janet Choi, Chief Medical Officer, Progyny
Lissa Kline, LCSW, Progyny

This show does not constitute medical advice.

Looking for more? Here are some related resources.

patient listening patiently to her provider
Top Myths About High Follicle Stimulating Hormone Levels | Progyny
group of happy schoolchildren
Developmental milestones in school-aged children | Progyny
progyny-logo
What to expect at a fertility clinic and lab | Progyny
DocTalk episode: STAR: AI meets fertility treatment
STAR: AI meets fertility treatment | Progyny
provider and patient looking at ipad
Saving on perimenopause and menopause prescription costs | Progyny